Neurological perspectives on voltage-gated sodium channels.
Eijkelkamp, N; Linley, JE; Baker, MD; Minett, MS; Cregg, R; Werdehausen, R; Rugiero, F; Wood, JN

© 2012 The Author
CC-BY-NC

For additional information about this publication click this link.
http://qmro.qmul.ac.uk/xmlui/handle/123456789/18436

Information about this research object was correct at the time of download; we occasionally make corrections to records, please therefore check the published record when citing. For more information contact scholarlycommunications@qmul.ac.uk
Neurological perspectives on voltage-gated sodium channels

Niels Eijkelkamp,1,* John E. Linley,1,* Mark D. Baker,2 Michael S. Minett,1 Roman Cregg,1 Robert Werdehausen,1,3 François Rugiero1 and John N. Wood1

1 Molecular Nociception Group, Wolfson Institute for Biomedical Research, University College London, Gower Street, London WC1E 6BT, UK
2 Neuroscience Institute of Cell and Molecular Science Barts and The London School of Medicine and Dentistry 4, Newark Street, London E1 2AT, UK
3 Department of Anaesthesiology, Medical Faculty, Heinrich-Heine-University Düsseldorf, Moorenstrasse 5, 40225 Düsseldorf, Germany

Correspondence to: Dr John Wood, Wolfson Institute for Biomedical Research (WIBR), University College London, Gower Street, Cruciform Building, London WC1E 6BT
E-mail: j.wood@ucl.ac.uk

Correspondence may also be addressed to: Dr Niels Eijkelkamp
E-mail: n.eijkelkamp@ucl.ac.uk

*These authors contributed equally to this work.

The activity of voltage-gated sodium channels has long been linked to disorders of neuronal excitability such as epilepsy and chronic pain. Recent genetic studies have now expanded the role of sodium channels in health and disease, to include autism, migraine, multiple sclerosis, cancer as well as muscle and immune system disorders. Transgenic mouse models have proved useful in understanding the physiological role of individual sodium channels, and there has been significant progress in the development of subtype selective inhibitors of sodium channels. This review will outline the functions and roles of specific sodium channels in electrical signalling and disease, focusing on neurological aspects. We also discuss recent advances in the development of selective sodium channel inhibitors.

Keywords: ion channel; genetics; pain; epilepsy; SCN1A
Abbreviations: TTX = tetrodotoxin; VGSC = voltage-gated sodium channel

Sodium channels

Structure and activity

The voltage-gated sodium channel (VGSC) gene family comprises nine homologous members SCN1A to SCN11A, which encode the sodium selective ion channels NaV1.1 to NaV1.9. Nax (SCN6A/SCN7A), though structurally related to VGSCs, is not activated by membrane depolarization, but rather by altered sodium concentrations (Goldin et al., 2000). Each large α-subunit (~260 kDa) contains four homologous domains DI–DIV, with each domain containing six transmembrane segments. One α-subunit alone is necessary and sufficient to form a functional channel; however α-subunits also associate with β-subunits (SCN1B to SCN4B), which modulate channel biophysics and trafficking. At resting membrane potentials, VGSCs are closed, requiring depolarization to be activated. Upon activation they contribute to the upstroke of the action potential in excitable cells (Fig. 1A and B). Channel opening...
Figure 1  Gating model and contribution of voltage-gated sodium channels to neuronal and cardiac action potential firing. Upper traces depict a cartoon representation of a whole-cell current clamp recording from a typical neuron (A) or cardiac myocyte (B). Dotted line indicates the resting membrane potential ($V_m$). Lower trace is temporally aligned to the upper trace and shows the change in sodium current ($I_{Na}$) during an action potential. Note a downward deflection of the trace reflects an inward movement of sodium ions into the cell. (1) At the resting membrane potential VGSCs are closed. A small depolarization of the neuronal membrane potential in response to sensory input or receptor input depolarizes the neuronal membrane potential to the threshold for VGSC activation (~50 mV). (2) VGSCs activate rapidly (~1 ms to peak) allowing the influx of sodium and depolarizing the membrane potential further, forming the upstroke of the action potential. Note that the peak sodium current correlates with the peak of the action potential. (3) Following activation the sodium channels inactivate resulting in a decrease in sodium current and repolarization of the neuronal membrane potential, contributing to the downstroke of the action potential. Recovery from inactivation allows the channels to participate in the next action potential. (C) Mechanism of voltage sensitive gating of VGSCs. The left channel represents a VGSC in a deactivated (closed) state. A small depolarization of the membrane potential causes a movement of the positively charged S4 voltage-sensor domain (green) leading to a conformational change in the protein and opening of the pore (middle channel). Following activation, the pore is rapidly occluded by the inactivation gate, resulting in inactivation of the sodium channel (right channel).
results in a rapid influx of sodium ions into the cell and further depolarization of the membrane potential towards the equilibrium potential for sodium ($\sim +60$ mV in most neurons). VGSCs close within milliseconds of opening, a process called fast inactivation that contributes to the downstroke of the action potential (Fig. 1C). In many neurons, inactivation of VGSCs is incomplete, resulting in a small persistent $Na^+$ current, which inactivates over a time period of tens of seconds. Functionally, the structure of the VGSCs can be divided into two parts with the transmembrane domains S1–S4 contributing to the voltage sensor and S5–S6 arranging to form the sodium selective pore (Stuhmer et al., 1989; Catterall et al., 2005). The molecular mechanism by which changes in membrane voltage confer a conformational change on voltage-gated ion channel proteins is through the movement of modular voltage sensors contained within the S4 segment of domains I–IV (Fig. 1C) (Alabi et al., 2007). The voltage sensors contain repeated motifs of positively charged amino acids followed by hydrophobic residues arranged in an $\alpha$-helix with a linear array of positively charged residues. Depolarization of the cell alters the electric field across the cell membrane resulting in the rapid movement of the DI–III S4 voltage sensors and a conformational change in the protein which opens the ion channel pore. Inactivation follows activation due to the intrinsically slower movement of the DI/V voltage sensor (Bosmans et al., 2008). The VGSC inactivation gate contains a trio of amino acids (IFM) located in a highly conserved intracellular loop connecting domains III and IV (West et al., 1992). Upon inactivation, the inactivation gate moves into the channel pore as shown by the altered accessibility of antibodies targeted to this domain (Vassilev et al., 1988, 1989), resulting in occlusion of the pore often depicted as a ball and chain type block (Fig. 1C). The channels remain in a refractory inactivated state until the cell membrane potential repolarizes, normally facilitated by the delayed activation of voltage-gated potassium channels.

Much of what is known about the molecular mechanism of voltage sensing derives from studies on voltage-gated potassium channels for which high-resolution crystal structures have been obtained. Using X-ray crystallography the structure of the S4 voltage sensor in the Archaea voltage-dependent potassium channel KvAP was modelled as a paddle (Jiang et al., 2003a, b). However, recent modelling of the bacterial sodium channel NaChBac reveals that the S4 voltage sensor segment is arranged in a 3(10) alpha helical conformation that slides in a linear fashion through a narrow groove formed by the S1, S2 and S3 segments (Yarov-Yarovoy et al., 2012). Recently, the crystal structure of a VGSC has been reported (Payandeh et al., 2011). Comparison with the previous open potassium channel structures showed that the voltage-sensor domains and the S4–S5 linkers dilate the central pore by pivoting together around a hinge at the base of the pore module (Payandeh et al., 2011). This newly described crystal structure of a prokaryotic VGSC shows that the basis of ion channel selectivity for $Na^+$ is different from potassium channels (Corry and Thomas, 2012).

**Persistent sodium currents**

All the kinetically fast transient channels (NaV1.1–1.7) appear quite similar in functional properties, but sodium channels sometimes generate much longer openings as a result of incomplete or defective fast inactivation. NaV1.9 gives rise to a low-threshold, persistent tetrodotoxin (TTX)-resistant Na$^+$ current in sensory neurons (Baker et al., 2003). Persistent sodium currents have also been recorded in cells that do not express NaV1.9, including cardiac and skeletal muscle (Patlak and Ortiz, 1986; Bohle and Benndorf, 1995), large diameter dorsal root ganglion neurons (Baker and Bostock, 1997) and cortical pyramidal neurons (Alzheimer et al., 1993; Schwindt and Crill, 1995). In some voltage-clamp protocols the amplitude of persistent current is just a few per cent of that of the transient current at the same potentials but is still functionally important. For mammalian primary sensory neurons, persistent currents activate at more negative potentials than the associated transient currents. The hyperpolarized voltage dependence of activation of persistent sodium currents allows these channels to operate as amplifiers of subthreshold depolarization, because their activation kinetics are fast and they operate over a strategic subthreshold membrane potential range with low potassium channel activation. Evidence from muscle fibre recordings indicates that NaV1.4 can generate persistent currents, and NaV1.6 generates such currents in cerebellar Purkinje neurons (Raman et al., 1997; Raman and Bean, 1997). The functional importance of persistent currents can be seen from the effects of SCN8A mutations that change neuron firing patterns and lead to ataxia in mice (Meisler et al., 2002, 2004). In addition, many epileptogenic mutations of SNC1A, SCN2A and SCN3A exhibit increased persistent currents (Meisler and Kearney, 2005). The implication of these findings is that specific blocking of channels with inactivation-defective gating might be a useful way of controlling membrane excitability within the nervous system (Lampl et al., 1998). In primary sensory neurons, persistent currents are preferentially targeted by local anaesthetics (Baker, 2000). Local anaesthetics can suppress ectopic firing in damaged sensory neurons without altering action potential properties (Devor et al., 1992), probably because the block of persistent currents takes the membrane potential further away from firing threshold.

**Resurgent sodium currents**

Resurgent currents, first observed in cerebellar Purkinje neurons (Raman and Bean, 1997) and present in dorsal root ganglion neurons (Cummins et al., 2005), may arise following relief of ultra-fast open-channel block (faster than pore block by the inactivation gate) mediated by yet undetermined proteins. In some neurons, sodium channels transiently open upon recovery from inactivation when the membrane potential is repolarized. This transient opening gives rise to a large inward tail current termed ‘resurgent current’ (Cannon and Bean, 2010). One possible mechanism for resurgent current involves the blockade of the channel pore by the C-terminus of $\beta 4$ subunit of sodium channels (Grieco et al., 2005; Bant and Raman, 2010). Resurgent currents have recently become an important topic in pain and myopathy research as sodium channel mutations involved in these pathologies were found to increase resurgent currents (Jarecki et al., 2010). Mutations in NaV1.4, NaV1.5 and NaV1.7 that lead to paramyotonia congenita, cardiac long QT syndrome/sudden infant death
syndrome and paroxysmal extreme pain disorder, respectively, all enhance resurgent currents, thereby affecting the firing properties of the cells. Although resurgent current can be observed with Na\textsubscript{\textalpha}1.4-, Na\textsubscript{\textalpha}1.5-, Na\textsubscript{\textalpha}1.6- and Na\textsubscript{\textalpha}1.7-based sodium channels in expression studies, in vivo resurgent currents have only been recorded from neurons and never from cardiac or skeletal muscle.

Many toxins affect sodium channel function by altering the gating of these channels. The wasp venom \(\beta\)-pompidolotoxin (\(\beta\)-PMTX) is able to produce resurgent currents through a molecular mechanism involving the slowing of sodium channel inactivation (Grieco and Raman, 2004). Another toxin, the Cn2 \(\beta\)-scorpion peptide, shifts the activation of Na\textsubscript{\textalpha}1.2 and Na\textsubscript{\textalpha}1.6 towards more hyperpolarized potentials by trapping the DI/II S4 voltage sensor in the inactivated rather than the closed state. A \(\beta\)-scorpion toxin also has the capability of producing resurgent currents by trapping the voltage sensor of human Na\textsubscript{\textalpha}1.6 channels and VGSC in mouse Purkinje cells (Schiavon et al., 2006). The data from these two studies strongly suggest that an increased open probability of sodium channels is a key requirement for the generation of resurgent currents. Very recently it has been suggested that the transient, resurgent and persistent phases of the sodium current in cerebellar granule cells are all interlinked through the \(\beta\)4 subunit (Bant and Raman, 2010). These results highlight the critical role that toxins play in unravelling gating mechanisms of sodium channels.

**Voltage-gated sodium channel function and disease association**

The nine different VGSC \(\alpha\)-subunits are differentially expressed (Table 1), and disruption of VGSC function can lead to a broad range of pathologies. The role of VGSCs in epilepsy and pain has been well established; however, there is increasing evidence of a role for VGSCs in other disorders including cancer, multiple sclerosis, muscle and immune disorders, autism, neurodegeneration and cardiovascular complications (Table 1). Human heritable disorders can now be mapped with relative ease. A number of disorders have been ascribed to mutations in genes encoding sodium channels and further genetic insights have been provided by analysis of targeted sodium channel mutations and gene deletion in mice (Table 1). The correlation between the clinical phenotype of patients with channel mutations and channel biophysical properties and observations in mouse models will be discussed later.

**Na\textsubscript{\textalpha}1.1 (SCN1A)**

Broadly expressed in the CNS, Na\textsubscript{\textalpha}1.1 expression may be preferentially expressed in inhibitory gamma-aminobutyric acidergic (GABAergic) neurons (Yu et al., 2006). The majority of the >700 associated SCN1A mutations are nonsense causing the autosomal dominant disorder Dravet’s syndrome. In addition, approximately two dozen SCN1A mutations have been identified in families with the milder disorder, generalized epilepsy with febrile seizures plus, which is characterized by short-lasting tonic–clonic seizures accompanied by fever (Meisler et al., 2010). Generalized epilepsy with febrile seizures plus mutations change expression and function of Na\textsubscript{\textalpha}1.1 channels due to both gain- and loss-of-function mutations. For example, the D188V mutation leads to impaired slow inactivation (Cossette et al., 2003), while the T875M mutation enhances slow inactivation (Spampanato et al., 2001). Both mutations lead to the same phenotype. Thus, the relationship between the clinical phenotypes and the functional defects is complex (reviewed in Ragsdale, 2008). Some linkage between specific genetic abnormalities and phenotype has been shown; SCN1A mutations are associated with early onset of febrile seizures/febrile seizures plus while SCN18 mutations are associated with later onset (Sijben et al., 2009).

The more detrimental severe myoclonic epilepsy of infancy (or Dravet’s syndrome) is associated with haploinsufficiency for SCN1A in 50–80% of severe myoclonic epilepsy of infancy patients caused by more deleterious nonsense and frameshift mutations in Na\textsubscript{\textalpha}1.1 (De Jonghe, 2011). In contrast to generalized epilepsy with febrile seizures plus, these mutations prevent channel expression or severely impair channel function. While loss-of-function mutations are common in Dravet’s syndrome, a gain-of-function mutation in SCN1A (R865G) has also been found (Volkers et al., 2011). SCN1A duplications and deletions are also found in patients with Dravet’s syndrome (Marini et al., 2009). More recently, de novo SCN1A mutations have been found in patients with the severe early infantile onset syndrome of malignant migrating partial seizures, also a severe epileptic encephalopathy (Carranza et al., 2011).

The severity of channel impairment has been suggested to underlie the different efficacies of some anti-epileptic drugs in treating either generalized epilepsy with febrile seizures plus or severe myoclonic epilepsy of infancy, of which many act through inhibiting VGSCs. For example, the sodium channel blocker lamotrigine is very effective for treating generalized epilepsy with febrile seizures plus, while it aggravates symptoms in patients with severe myoclonic epilepsy of infancy (Guerrini et al., 1998). The efficacy of some frontline anti-epileptic drugs, which often work through stabilizing channels in the inactive state, has been suggested to be influenced by a polymorphism that modifies splicing of Na\textsubscript{\textalpha}1.1 leading to altered inactivation (Fletcher et al., 2011). Studies on Scn1a\textsuperscript{+/−} mice have shown that deletion of Na\textsubscript{\textalpha}1.1 leads to impaired firing of GABAergic inhibitory hippocampal interneurons (Catterall and Kalume, 2010) and cerebellar GABAergic Purkinje neurons (Kalume et al., 2007). The impaired functioning of inhibitory GABAergic neurons may contribute to seizures, ataxia, spasticity and failure of motor coordination observed in these mice.

It is interesting to note that targeting Na\textsubscript{\textalpha}1.1 to treat epilepsy is not the only possible therapeutic strategy. Mice with haploinsufficiency for both Na\textsubscript{\textalpha}1.1 and Na\textsubscript{\textalpha}1.6 showed reduced susceptibility to drug-induced seizures compared with Na\textsubscript{\textalpha}1.1 heterozygotes (Martin et al., 2007). In contrast with Na\textsubscript{\textalpha}1.1, Na\textsubscript{\textalpha}1.6 is highly expressed in excitatory neurons (Caldwell et al., 2000). Thus it seems that the excitatory and inhibitory balance in the brain is restored by Na\textsubscript{\textalpha}1.6 mutations that reduce firing of excitatory neurons. Finally, Na\textsubscript{\textalpha}1.1 mutations are also associated with familial hemiplegic migraine type 3 (Dichgans et al., 2005), an autosomal
Table 1 Expression patterns in relation to known effects of human and mouse mutants of VGSCs

<table>
<thead>
<tr>
<th>Channel</th>
<th>Gene</th>
<th>Major expression</th>
<th>Channel disease association</th>
<th>Phenotype of mouse mutants</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nav1.1</td>
<td>SCN1A</td>
<td>CNS (Westenbroek et al., 1989), PNS</td>
<td>Epilepsy (Escayg et al., 2000), migraine (Dichgans et al., 2005), autism (Weiss et al., 2003)</td>
<td>(−/−) Ataxia and death at P15 (Yu et al., 2006); (+ / −) spontaneous seizures and periodic attacks after P21 (Yu et al., 2006)</td>
</tr>
<tr>
<td>Nav1.2</td>
<td>SCN2A</td>
<td>CNS (Westenbroek et al., 1992), PNS</td>
<td>Epilepsy (Sugawara et al., 2001; Heron et al., 2002; Liao et al., 2010) (GOF), autism (Weiss et al., 2003), episodic ataxia (GOF) (Liao et al., 2010)</td>
<td>(−/−) Perinatal lethal (Planells-Cases et al., 2000)</td>
</tr>
<tr>
<td>Nav1.3</td>
<td>SCN3A</td>
<td>CNS (Whitaker et al., 2001; Hains et al., 2003), PNS</td>
<td>Epilepsy (GOF) (Holland et al., 2008b)</td>
<td>(−/−) and (+ / −) nociceptor specific normal acute inflammatory and neuropathic pain (Nassar et al., 2006)</td>
</tr>
<tr>
<td>Nav1.4</td>
<td>SCN4A</td>
<td>Skeletal muscle</td>
<td>Hyperkalemic periodic paralysis (GOF) (Ptacek et al., 1996), hypokalaemic periodic paralysis (altered gating current) (Sokolov et al., 2007)</td>
<td>Unknown</td>
</tr>
<tr>
<td>Nav1.5</td>
<td>SCN5A</td>
<td>Cardiac muscle (Rogart et al., 1989)</td>
<td>Brugada syndrome (Chen et al., 1998) (LOF); long QT syndrome 3 (Zimmer and Surber, 2008) (GOF); atrial fibrillation</td>
<td>(−/−) Intrauterine lethality with severe defects in ventricular morphogenesis; (+ / −) decreased atrial and atrio-ventricular conduction progressed with age (Papadatos et al., 2002); (+ / +) knockin model of LQT3 resulted in spontaneous ventricular arrhythmias (Nuyens et al., 2001)</td>
</tr>
<tr>
<td>Nav1.6</td>
<td>SCN8A</td>
<td>CNS, PNS (Black et al., 1996), smooth muscle</td>
<td>Mental retardation, pancerebellar atrophy, ataxia (Trudeau et al., 2006); infantile experimental encephalopathy (Veeramah et al., 2012)</td>
<td>(−/−) Reduced cold allodynia in a neuropathic pain model; increased visceral inflammatory pain (Leo et al., 2010); reduced thermal but not mechanical hyperalgesia in inflammatory model (Priest et al., 2005)</td>
</tr>
<tr>
<td>Nav1.7</td>
<td>SCN9A</td>
<td>PNS (Toledo-Aral et al., 1997)</td>
<td>Pain free (LOF) (Cox et al., 2006, 2010); erythromalgia (GOF) (Yang et al., 2004), paroxysmal extreme pain disorder (reduced fast inactivation) (Fertileman et al., 2006), anosmia (Goldberg et al., 2007)</td>
<td>(−/−) Reduced cold allodynia in a neuropathic pain model; increased visceral inflammatory pain (Leo et al., 2010); reduced thermal but not mechanical hyperalgesia in inflammatory model (Prist et al., 2005)</td>
</tr>
<tr>
<td>Nav1.8</td>
<td>SCN10A</td>
<td>PNS (Akopian et al., 1999), heart (Chambers et al., 2010)</td>
<td>SNP rs6799970 (G → A) results in prolonged cardiac conduction (Chambers et al., 2010)</td>
<td>(−/−) Reduced cold allodynia in a neuropathic pain model; increased visceral inflammatory pain (Leo et al., 2010); reduced thermal but not mechanical hyperalgesia in inflammatory model (Prist et al., 2005)</td>
</tr>
<tr>
<td>Nav1.9</td>
<td>SCN11A</td>
<td>PNS (Dib-Hajj et al., 1998)</td>
<td>Unknown</td>
<td>(−/−) Insensitivity to blunt mechanical pressure; some deficits in inflammatory pain(Akopian et al., 1999; Papadatos et al., 2002; Abrahamson et al., 2008); prolonged cardiac PR interval (Chambers et al., 2010)</td>
</tr>
<tr>
<td>NaX</td>
<td>SCN7A</td>
<td>Circumventricular organs (Hiyama et al., 2004)</td>
<td>Unknown</td>
<td>(−/−) Insensitivity to blunt mechanical pressure; some deficits in inflammatory pain(Akopian et al., 1999; Papadatos et al., 2002; Abrahamson et al., 2008); prolonged cardiac PR interval (Chambers et al., 2010)</td>
</tr>
<tr>
<td>j1</td>
<td>SCN1B</td>
<td>CNS, cardiac muscle (Isom et al., 1992)</td>
<td>Epilepsy (GEF +) (Scheffer et al., 2007), Dravet’s syndrome (Patino et al., 2009) Brugada syndrome (Watanabe et al., 2008) (defective trafficking); atrial fibrillation (LOF) (Watanabe et al., 2009)</td>
<td>(−/−) Spontaneous seizures (Patino et al., 2009); (+ / −) normal seizure susceptibility (Patino et al., 2009); (− / −) reduced resurgent sodium current in cerebellar neurons (Brackenbury et al., 2010); (− / +) hypoglycaemia (Ernst et al., 2009); (− / −) long QT interval (Lopez-Santiago et al., 2007)</td>
</tr>
<tr>
<td>j2</td>
<td>SCN2B</td>
<td>PNS (Lopez-Santiago et al., 2006)</td>
<td>Atrial fibrillation (LOF) (Watanabe et al., 2009)</td>
<td>(−/−) Neuroprotective in model of multiple sclerosis (O’Malley et al., 2009); (− / −) increased sensitivity to noxious heat and reduced inflammatory pain (Lopez-Santiago et al., 2006)</td>
</tr>
<tr>
<td>j3</td>
<td>SCN3B</td>
<td>Cardiac muscle, CNS, skeletal muscle (Stevens et al., 2001)</td>
<td>Idiopathic ventricular fibrillation (Valdivia et al., 2010), atrial fibrillation (DN mutants) (Wang et al., 2010a), Brugada syndrome (defective trafficking) (Hu et al., 2009), sudden infant death syndrome (Tan et al., 2010)</td>
<td>Atrial and ventricular conduction abnormalities (Hakim et al., 2008, 2010)</td>
</tr>
<tr>
<td>j4</td>
<td>SCN4B</td>
<td>CNS, PNS (Yu et al., 2003)</td>
<td>Long QT syndrome (Medeiros-Domingo et al., 2007), Sudden infant death syndrome (Tan et al., 2010)</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

DN = dominant negative; GOF = gain-of-function; LOF = loss-of-function; PNS = peripheral nervous system; GEF + = generalized epilepsy with febrile seizures plus; (−/−) = homozygous knockout; (+ / −) = heterozygous knockout; med = motor endplate disease.
dominant severe subtype of migraine with aura characterized by hemiparesis during the attacks. Genome-wide linkage analysis revealed three families with the same missense mutation in SCN1A (Q1489K). This mutation resulted in complex changes in channel gating including a depolarizing shift in the voltage dependence of inactivation, accelerated recovery from inactivation and increased persistent current (Cestele et al., 2008). These biophysical changes could cause either hyper- or hypoexcitability depending on the firing frequency and resting membrane potential of the neuron. More recently, whole exome sequencing has identified candidate genes with de novo mutations, including SCN1A, in sporadic autism spectrum disorders (O’Roak et al., 2011, 2012).

**Na\(_\text{V}\)1.2 (SCN2A)**

Na\(_\text{V}\)1.2 is abundantly expressed in the adult CNS, particularly in the cortex and hippocampus (Westenbroek et al., 1989), where it is primarily expressed in unmyelinated axons and dendrites (Boiko et al., 2001). Early in development, Na\(_\text{V}\)1.2 is highly expressed in regions destined to become nodes of Ranvier and is replaced during development by Na\(_\text{V}\)1.6 (Boiko et al., 2001; Kaplan et al., 2001). Na\(_\text{V}\)1.2 knockout mice die perinatally from neuronal apoptosis and hypoxia (Planells-Cases et al., 2000). In humans, Na\(_\text{V}\)1.2 mutations are associated with inherited epilepsy, mainly benign familial neonatal-infantile seizures (Heron et al., 2002) and less frequently with other forms of epilepsy such as generalized epilepsy with febrile seizures plus (Sugawara et al., 2001). Benign familial neonatal-infantile seizure is an autosomal dominant disorder characterized by afebrile seizures with onset within 4 months after birth and spontaneous remission within the first year of life, without residual neurological deficits. Three separate benign familial neonatal-infantile seizures causing mutations in Na\(_\text{V}\)1.2 resulted in reduced plasma membrane expression while having varied effects on channel activation and inactivation (Misra et al., 2008). Although there is little consensus over the pathological mechanisms, studies have demonstrated that either gain- or loss-of-function mutations of Na\(_\text{V}\)1.2 are associated with disease. A link between Na\(_\text{V}\)1.2 and autism has been reported at low frequency (1/229 autism families studied), resulting in mutation of the calmodulin binding domain of Na\(_\text{V}\)1.2 and reduced calmodulin-binding affinity (Weiss et al., 2003). De novo mutations revealed by whole-exome sequencing including two independent nonsense mutations in SCN2A, are strongly associated with autism (Sanders et al., 2012).

**Na\(_\text{V}\)1.3 (SCN3A)**

Na\(_\text{V}\)1.3 is widely expressed in the human brain and has a predominantly somatodendritic expression pattern (Whitaker et al., 2001). In contrast to many of the other VGSC genes, there are as yet no clear monogenic diseases associated with SCN3A mutation. However, a small study of patients with cryptogenic paediatric partial epilepsy revealed a mutation in SCN3A (K354Q) that led to an increase in persistent current and induced epileptiform hyperexcitability in hippocampal neurons (Holland et al., 2008a; Estacion et al., 2010). Animal studies have focused on a possible role of Na\(_\text{V}\)1.3 in neuropathic pain. Following axotomy and inflammation in mice, Na\(_\text{V}\)1.3 transcript levels increase in sensory neurons (Waxman et al., 1994b; Dib-Hajj et al., 1999). Antisense knockdown of Na\(_\text{V}\)1.3 expression attenuates pain-related behaviour associated with spinal cord injury and chronic constriction injury (Hains et al., 2004) but not alldynia in the spared nerve injury model (Lindia et al., 2005). However, Na\(_\text{V}\)1.3 knockout mice, where the gene was deleted globally or selectively in nociceptive neurons, showed normal pain behaviour and normal development of neuropathic pain in the Chung model of neuropathic pain (Nassar et al., 2006). Although several lines of investigation have implicated Na\(_\text{V}\)1.3 as a candidate drug target to treat neuropathic pain, this study does not support an essential role for Na\(_\text{V}\)1.3 in neuropathic pain.

**Na\(_\text{V}\)1.4 (SCN4A)**

Na\(_\text{V}\)1.4 is responsible for the generation and propagation of action potentials that initiate muscle contraction. Currently, five hereditary sodium channelopathies of skeletal muscle involving Na\(_\text{V}\)1.4 mutations have been identified, such as hyperkalaemic periodic paralysis, hypokalaemic periodic paralysis, paramyotonia congenita, potassium-aggravated myotonia and congenital myasthenic syndrome (Jurkat-Rott et al., 2010). Hypokalaemic periodic paralysis and normokalaemic periodic paralysis causing mutations map to the Na\(_\text{V}\)1.4 voltage sensor, resulting in ionic leak through the gating pore allowing sustained inward sodium flux at negative membrane potentials (Sokolov et al., 2010). In contrast, mutations associated with paramyotonia congenita and hyperkalaemic periodic paralysis are widespread in the Na\(_\text{V}\)1.4 protein and either enhance activation or impair inactivation resulting in hyperexcitability. Mutations in KCNA1 and SCN4A have been found in a patient with episodic ataxia and paramyotonia congenita. Coexistence of these two ion channelopathies in this patient raises the possibility of a role of sodium channels in episodic ataxias (Rajakulendran et al., 2009).

**Na\(_\text{V}\)1.5 (SCN5A)**

Several syndromes leading to sudden cardiac death have been linked to Na\(_\text{V}\)1.5. For example, over 80 SCN5A mutations have been identified in patients with long QT syndrome type 3 (Zimmer and Surber, 2008). These mutations mostly disrupt fast inactivation, thereby causing persistent sodium currents (Bennett et al., 1995). Similarly, Brugada syndrome also leads to sudden cardiac death that may account for up to 50% of all sudden cardiac deaths in young individuals without structural heart disease. SCN5A mutations were found in ~20% of patients with Brugada syndrome (Kaplinger et al., 2010) resulting in channel loss-of-function through a number of different mechanisms including expression of non-functional Na\(_\text{V}\)1.5 (Valdivia et al., 2004; Hsueh et al., 2009), decreased protein expression (Knydt et al., 2001), impaired membrane trafficking (Baroudi et al., 2001, 2002) or defective channel inactivation (Hsueh et al., 2009). Although Na\(_\text{V}\)1.5 has been mainly linked to cardiac disease, a more recent report shows a novel SCN5A mutation in a patient with idiopathic epilepsy who died in sudden unexpected death in epilepsy (SUDEP) (Aurlien et al., 2009).
Interestingly, VGSC upregulation has been associated with several strongly metastatic carcinomas, leading to the hypothesis that VGSC upregulation may ‘switch’ the cancerous cell to a highly invasive state (Onkal and Djamgoz, 2009). Some cancers express embryonic/neonatal VGSC splice variants, for example, a neonatal isoform of NaV1.5 (seven amino acid differences) is the predominant (>-80%) VGSC in human metastatic breast cancer (Fraser et al., 2005) as well as neuroblastoma (Ou et al., 2005).

**Na\textsubscript{\text{v}}1.6 (SCN8A)**

Na\textsubscript{\text{v}}1.6 is broadly expressed in the nervous system in a variety of cells including Purkinje cells, motor neurons, pyramidal and granule neurons, glial cells and Schwann cells and is enriched at the nodes of Ranvier (Caldwell et al., 2000; Kearney et al., 2002). Mutation in SCN8A is not a common cause of human disease although a patient with a heterozygous mutation in SCN8A has been described with mental retardation, pancerebellar atrophy and ataxia (Trudeau et al., 2000). This mutation caused a C-terminal truncation of Na\textsubscript{\text{v}}1.6 resulting in predicted loss of channel function. Naturally occurring med mutant Na\textsubscript{\text{v}}1.6 knockout mice show a range of movement disorders including tremor, ataxia, dystonia and paralysis (Meisler et al., 2002, 2004). Mutant mice are also reported to have disordered sleep patterns with a chronic impairment of REM sleep and enhanced spatial memory (Papale et al., 2010). In Purkinje cells of Na\textsubscript{\text{v}}1.6 knockout mice, resurgent currents are reduced and spontaneous and evoked firing was attenuated (Raman et al., 1997). Recently a de novo pathogenic SCN8A mutation with greatly increased persistent current was identified in a case of SUDEP with infantile epileptic encephalopathy (Veeramah et al., 2012). Persistent Na\textsubscript{\text{v}}1.6 activity can trigger axonal injury within white matter axons during experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis (Crane et al., 2004). In non-excitable cells such as macrophages, Na\textsubscript{\text{v}}1.6 is expressed at an intracellular location on podosomes (Carrithers et al., 2009a). In this study, inhibition of Na\textsubscript{\text{v}}1.6 with TTX or by genetic ablation was effective at reducing invasion of macrophages into melanoma. Similarly, a non-neuronal role for Na\textsubscript{\text{v}}1.6 contributing to the invasiveness of cervical carcinomas has been suggested (Hernandez-Plata et al., 2012). This suggests that targeting Na\textsubscript{\text{v}}1.6 in non-neuronal tissue might have therapeutic potential to treat cancer or autoimmune disorders such as multiple sclerosis (Carrithers et al., 2009b). However, the essential role of Na\textsubscript{\text{v}}1.6 in many neurological functions may make this a difficult task.

**Na\textsubscript{\text{v}}1.7 (SCN9A)**

Na\textsubscript{\text{v}}1.7 is expressed in peripheral sensory neurons innervating the skin, viscera and orofacial region (dorsal root and trigeminal ganglia) as well as sympathetic neurons and olfactory epithelia (Toledo-Aral et al., 1997; Weiss et al., 2011). A number of human heritable pain disorders map to mutations in SCN9A, the gene encoding Na\textsubscript{\text{v}}1.7 (Dib-Hajj et al., 2010). Dominant gain-of-function mutations lead to inherited primary erythromelalgia, which is characterized by bilateral burning pain of the feet/lower legs and hands, elevated skin temperature of affected areas and reddened extremities (Yang et al., 2004). Additionally, dominant gain-of-function mutations can cause paroxysmal extreme pain disorder which is characterized by episodic burning pain of the rectum, ocular and mandibular regions (Fertleman et al., 2006). Rare recessive loss-of-function conditions can cause an inability to experience pain (Cox et al., 2006; Ahmad et al., 2007) and anorganic (Weiss et al., 2011).

Biophysical characterization of the Na\textsubscript{\text{v}}1.7 mutations present in patients with erythromelalgia shows a significant hyperpolarizing shift in voltage dependence of activation (Cummins et al., 2007), resulting in gain-of-function. The Na\textsubscript{\text{v}}1.7 mutations underlying paroxysmal extreme pain disorder, where mechanical stimulation evokes excruciating pain (Fertleman et al., 2006), attenuate the fast inactivation of Na\textsubscript{\text{v}}1.7 resulting in persistent sodium currents. Such a deficit in inactivation is predicted to produce prolonged bursts of action potentials leading to increased nociceptive signaling. In mouse studies, selective knockout of Na\textsubscript{\text{v}}1.7 expression in Na\textsubscript{\text{v}}1.8-positive nociceptors lead to a loss of acute noxious mechanosensation and inflammatory pain (Nassar et al., 2004), while deletion of Na\textsubscript{\text{v}}1.7 in all sensory neurons leads to additional loss of noxious thermosensation (Minett et al., 2012). These data suggest that Na\textsubscript{\text{v}}1.7 expressed within Na\textsubscript{\text{v}}1.8-positive sensory neurons are important for acute noxious mechanosensation, whilst Na\textsubscript{\text{v}}1.7 expressed within Na\textsubscript{\text{v}}1.8 negative dorsal root ganglion neurons are essential for acute noxious thermosensation. Furthermore, no effect on neuropathic pain behaviour was observed in mice that lack expression of Na\textsubscript{\text{v}}1.7 in Na\textsubscript{\text{v}}1.8-positive sensory neurons (Nassar et al., 2005). This is also true for mice in which Na\textsubscript{\text{v}}1.7 has been deleted from all dorsal root ganglion neurons. In contrast, mice in which Na\textsubscript{\text{v}}1.7 is deleted from all sensory neurons as well as sympathetic neurons show a dramatic reduction in mechanical hypersensitivity following a surgical model of neuropathic pain, demonstrating an important role for Na\textsubscript{\text{v}}1.7 in sympathetic neurons in the development of neuropathic pain (Minett et al., 2012). Overall, the role of Na\textsubscript{\text{v}}1.7 in human as well as animal pain perception highlights Na\textsubscript{\text{v}}1.7 as an important analgesic drug target.

Na\textsubscript{\text{v}}1.7 is not only implicated in pain perception. Weiss et al. (2011) demonstrated that Na\textsubscript{\text{v}}1.7 is an essential requirement for odour perception in both mice and humans. Surprisingly, Na\textsubscript{\text{v}}1.7 is required for synaptic signalling from the primary olfactory neurons to mitral cells, and the release of substance P from nociceptive neurons has also been shown to be Na\textsubscript{\text{v}}1.7-dependent (Weiss et al., 2011; Minett et al., 2012).

**Na\textsubscript{\text{v}}1.8 (SCN10A)**

Na\textsubscript{\text{v}}1.8 is a TTX-resistant sodium channel subtype that is expressed in nociceptive sensory neurons (Akopian et al., 1999) and acts as a major contributor to the upstroke of action potentials (Renganathan et al., 2001). Na\textsubscript{\text{v}}1.8 is essential in maintaining the excitability of nociceptors at low temperatures (Zimmermann et al., 2007), becoming the sole electrical impulse generator at temperatures <10°C. This is caused by enhanced slow inactivation of TTX-sensitive channels in response to cooling, whereas inactivation of Na\textsubscript{\text{v}}1.8 is cold resistant. Behavioural studies of mice in which Na\textsubscript{\text{v}}1.8 expressing sensory neurons are ablated...
show loss of response to noxious cold and noxious mechanical stimuli (Abrahamsen et al., 2008). Antisense studies have shown an important role for NaV1.8 channels in inflammatory pain (Khasar et al., 1998). Antisense oligonucleotides attenuate the development and maintenance of neuropathic pain in rats (Lai et al., 2002; Joshi et al., 2006) while small interfering RNA selective knockdown of NaV1.8 reverses mechanical allodynia (Dong et al., 2007). However, NaV1.8 knockout mice as well as NaV1.7/1.8 double knockout mice show normal neuropathic pain behaviour (Kerr et al., 2001; Nassar et al., 2005). However, selective blockers of NaV1.8 such as A-803467 (Jarvis et al., 2003) and ambroxol (Gaida et al., 2005) successfully suppress various pain symptoms and neuropathic pain in rats. A recent genome wide association study has identified a single nucleotide polymorphism in NaV1.8 which was associated with prolonged cardiac conduction (Chambers et al., 2010) (longer P-wave duration, PR interval and QRS duration), thereby providing evidence that NaV1.8 has a functional role in the heart, probably through effects on innervation rather than cardiac muscle.

NaV1.9 (SCN11A)

NaV1.9 is the most recently discovered VGSC subtype (Dib-Hajj et al., 1998). It is a marker of primary nociceptors (Fang et al., 2002) and is also expressed in the enteric nervous system (Rugiero et al., 2003). NaV1.9 is a biophysically unique sodium channel which generates TTX-resistant currents that have very slow gating kinetics (Dib-Hajj et al., 2002). The current generated by NaV1.9 is ‘persistent’ and can be activated at potentials close to resting membrane potential (~ −60 mV). Although the activation kinetics are too slow to contribute to the upstroke of an action potential, the channel acts as a modulator of membrane excitability by contributing regenerative inward currents over a strategic membrane potential range both negative to, and overlapping with the voltage-threshold for other transient sodium channels. While a selective blocker of NaV1.9 does not exist at present, SCN11A knockout mice exhibit a clear analgesic phenotype (Priest et al., 2005; Amaya et al., 2006), confirming NaV1.9 is an important player in generating hyperalgesia in inflammatory pain states. This appears to be explicable by changes in the properties of distal primary afferents. The response to inflammatory mediators is suppressed in NaV1.9 knockout mice consistent with the immunocytochemical localization of the channel at unmyelinated nerve endings (Black and Waxman, 2002; Padilla et al., 2007), and the remarkable functional plasticity of the current, known to be under G-protein pathway control via protein kinase C (Baker et al., 2003; Baker, 2005). Overall, therapeutically targeting NaV1.9 may help regulate pain thresholds following inflammation or injury.

β-Subunits of voltage-gated sodium channels

β-Subunits of VGSCs belong to the immunoglobulin superfamily of cell adhesion molecules and associate with α-subunits in two ways: covalently in the case of β2 and β4 subunits and non-covalently for β1 and β3 subunits (Patino and Isom, 2010). VGSC β-subunit expression is widespread both in excitable and non-excitable tissues (Patino and Isom, 2010). Although reported effect sizes vary, β-subunits shift the voltage-dependent gating of VGSC in heterologous expression systems (Zhao et al., 2011). In humans, mutations in β-subunits have been linked to numerous cardiac and epilepsy related diseases (Table 1). Heterozygous β1 mutations have been identified in seven families with generalized epilepsy with febrile seizures plus (Scheffer et al., 2007), (4–6% of generalized epilepsy with febrile seizures plus patients) with the most common mutation being C121W, which leads to impaired trafficking of VGSC to the axon initial segment (Wimmer et al., 2010). A human SCN1B epilepsy-related mutation (G257R) unique to a splice variant of β1A has been proposed to contribute to epilepsy through a mechanism that includes intracellular retention β1 resulting in aberrant neuronal path-finding (Patino et al., 2011). Mice heterozygous for β1 (C121W) displayed behavioural arrest at elevated core temperatures and enhanced axon initial segment excitability, which is proposed to be due to a hyperpolarized shift in the voltage dependence of activation of VGSC expressed at the axon initial segment (Wimmer et al., 2010). Mutations in all four β-subunits have been linked to cardiac pathologies including Brugada syndrome (β1 and β3), atrial fibrillation (β1, β2 and β3), ventricular fibrillation (β3) and long QT syndrome (β4) (Table 1). Mutations in β3 and β4 have also been linked to sudden infant death syndrome (found in 1% of cases) due to reduced peak sodium current through NaV1.5 and enhanced ‘late sodium current’ (Tan et al., 2010).

Expression levels of VGSC β-subunits vary in different pathological conditions (nerve injury, pain, Huntington’s disease) and knockout models of VGSC β-subunits display pain, epilepsy and ataxia phenotypes (Patino and Isom, 2010), suggesting that the range of VGSC β-subunit roles in pathological conditions may be wider than known. Interestingly, recent reports also show that the affinity and efficacy of VGSC inhibitors can be dramatically altered by changing β-subunit expression levels (Uebachs et al., 2010; Wilson et al., 2011) and that β-subunit expression levels change during diseases such as Huntington’s disease (mouse model) (Oyama et al., 2006) and after nerve injury (Pertin et al., 2005). It remains to be seen whether this altered pharmacology of α-β complexes can be utilized to produce VGSC blockers with higher selectivity and efficacy in vivo.

VGSC β-subunits also interact with the extracellular matrix as well as the cytoskeleton and intracellular signalling molecules (Isom, 2002; Brackenbury and Isom, 2011). Enzymatic cleavage leads to production of a soluble ectodomain and membrane bound C-terminal fragment, which have been implicated in the regulation of cell–cell contact and neurite outgrowth (Wong et al., 2005). The β4-subunit was recently identified as a novel substrate of the β-secretase, BACE1, an enzyme implicated in the pathogenesis of Alzheimer’s disease (Huth et al., 2011). In BACE1 knockout mice, the decay of the resurgent sodium current recorded from Purkinje cells was found to be slowed and could be modelled as a decrease in open pore block consistent with proteolytic modification of β4.
Sodium channel trafficking and disease

The pivotal role of sodium channels in electrical signalling requires targeting of VGSCs to the correct cellular location. High channel densities of VGSCs can be found at the axon initial segment and nodes of Ranvier as part of complex protein aggregates (Hedstrom and Rasband, 2006). Cytoplasmatic proteins regulate expression and function of VGSCs through binding to the intracellular domain of VGSCs, that are, in contrast to the extracellular domain, relatively divergent (Wood et al., 2004). To date, several studies have focused on identifying VGSC-associated proteins of which some are involved in trafficking (Diss et al., 2004; Shao et al., 2009; Leterrier et al., 2010). For example NaV1.8 requires the expression of the annexin p11 subunit, which binds to the N-terminal region of the channel to facilitate cell-surface expression of the channel (Okuse et al., 2002). Nerve growth factor upregulation of functional NaV1.8 expression, important in inflammatory pain appears to be indirectly mediated through enhanced p11 expression and trafficking (Okuse et al., 2002; Poon et al., 2004). In addition, the interaction of the N-terminus of NaV1.6 with microtubule-associated protein Map1b facilitates trafficking of NaV1.6 to neuronal surfaces (O’Brien et al., 2012).

A variety of protein kinases have been shown to regulate the trafficking of VGSCs to the cell membrane or to specialized membrane domains, such as lipid rafts (reviewed in Shao et al., 2009). Stimulation of the β2-adrenergic receptor leads to localization of cardiac NaV1.5 to caveolin-enriched membrane domains resulting in increased function and thereby possibly promoting cardiac arrhythmias (Yarbrough et al., 2002). Moreover, trafficking of intracellular pools of the sensory neuron-specific VGSCs NaV1.8 and NaV1.9 has been implicated in enhanced pain sensitivity (Dib-Hajj et al., 2010).

The co-factors required for NaV1.9 expression have not been defined, but this channel can only be functionally expressed in dorsal root ganglion neurons where it rescues the expression of persistent current in NaV1.9 knockout neurons (Ostman et al., 2008).

A number of VGSC mutants found in several human diseases have been found to be trafficking-deficient and may give insights into key protein regions/domains important for the regulation of VGSC trafficking (Table 1). Trafficking defects may arise due to improper protein folding or altered binding to essential chaperones within the endoplasmic reticulum, ultimately leading to endoplasmic reticulum retention and/or protein degradation. Alternatively, VGSC domains that are crucial for binding to associated proteins regulating VGSCs localization/functioning may be affected. An important family of scaffolding proteins, ankyrins, is responsible for the localization of structurally diverse membrane-associated and cytosolic protein, including VGSCs. Ankyrin-G is important in clustering NaV1.2 and NaV1.6 into nodes of Ranvier and axon initial segments (Jenkins and Bennett, 2001; Garrido et al., 2003). A nine-residue motif has been characterized in the Dil-III loop that is critical for ankyrin-G binding. This sequence is highly conserved within all VGSC isoforms and is almost identical between NaV1.2, NaV1.5 and NaV1.6 (Lemailliet al., 2003). Mutation of the ankyrin-G binding site of NaV1.6 prevents clustering at the axon initial segments (Gasser et al., 2012). A mutation associated with Brugada syndrome has been found within this ankyrin-G-binding motif of NaV1.5. This mutation (E1053K) abolished ankyrin-G binding resulting in a loss of membrane expression in cardiac myocytes (Mohler et al., 2004). Other Brugada syndrome mutations in NaV1.5 have been shown to be associated with defective trafficking/surface localization emphasizing the importance of correct targeting of this protein for cardiac function (Baroudi et al., 2001, 2002; Kyndt et al., 2001; Valdivia et al., 2002; Bezizza et al., 2003; Herfst et al., 2003; Ruan et al., 2010).

In patients with long QT syndrome, mutations in NaV1.5-associated genes have been found, such as ankyrin-B and SCN4B (Saenen and Vrints, 2008). β-Subunits regulate the surface density and the biophysical properties of the channel complex (Shao et al., 2009) and knockout mice lacking β2 subunit show reduced VGSC surface expression (Chen et al., 2002). Moreover, a recent report showed that a loss-of-function mutation of the SCN3B-encoded channel β3 subunit (Navb3–V54G) is associated with a case of idiopathic ventricular fibrillation. This mutation caused a trafficking defect of NaV1.5 to the plasma membrane (Valdivia et al., 2010). Conversely, β-subunits have also been shown to rescue a trafficking-defective NaV1.1 mutant (Rusconi et al., 2007).

Four mutations in the SCN1B gene have been described that lead to an inherited generalized epilepsy with febrile seizures plus. Both mutations occur in a domain of the β1 subunit that is important for the regulation of the subcellular localization of VGSCs within neurons (Wimmer et al., 2010). An epilepsy causing SCN1A loss-of-function mutation within the region of the C-terminal cytoplasmic domain (M1841T) that is involved in interactions with accessory subunits has been identified as trafficking defective. Importantly, trafficking of this mutant could be rescued by modulatory proteins, such as β-subunits, calmodulin or G protein β2/3 and the anti-epileptic drug phenytoin (Rusconi et al., 2007). However, phenytoin cannot be used therapeutically as it also blocks channel function.

The broadly expressed 20 amino acid IQ motif also found in VGSCs binds to the ubiquitously expressed Ca2+-sensing protein calmodulin. Mutation of the NaV1.4 calmodulin-binding IQ motif showed that this domain is indispensable for normal channel expression and functioning (Biswas et al., 2008). A mutation of SCN2A that reduced affinity for calcium-bound calmodulin was observed in a patient with autism (Weiss et al., 2003). Finally, a recent study has identified two novel non-truncating missense mutations in families with congenital insensitivity to pain that were mapped within the pore domain of SCN9A. These mutations cause complete loss-of-function as well as membrane expression of the channel (Cox et al., 2010).

There are no effective drugs in use that target trafficking of VGSC. However, some reports have shown that mecloxetine, a drug used to inhibit persistent sodium current and to shorten QT interval, rescues trafficking in defective SCN5A mutants (Valdivia et al., 2002; Ruan et al., 2010). The rescue of trafficking of these mutants, however, counteracts the effectiveness of the drug as the increased trafficking may exacerbate the QT
persistence due to increased expression of the mutant protein. In contrast, phenytoin not only rescues a trafficking-defective SCN1A mutant but also blocks the channel (Rusconi et al., 2007). Thus, drugs that can act as folding chaperones to rescue mutant protein, but do not block channel function, are required.

Although effective drugs have yet to be designed to modulate VGSC expression by interfering with the trafficking pathway, some promising results have been obtained with the anti-epileptic and anti-nociceptive drug gabapentin and its derivatives. These drugs exert their effect primarily via inhibition of trafficking of the voltage-gated \( \alpha \delta 12 \) calcium channel subunit (Heblich et al., 2008; Hendrich et al., 2008) indicating that drugs targeting trafficking may be useful in VGSC-related pathologies.

**Toxins as useful tools to understand voltage-gated sodium channel function and pharmacology**

Toxins have been useful in understanding the structural and molecular determinants of VGSC gating through their modifying actions on the gating of VGSCs (Catterall et al., 2007). At least six toxin-binding sites (sites 1–6) for toxins have been localized to specific regions of sodium channels. The site of interaction of a number of more recently characterized toxins, including the inhibitory \( \mu \)O-conotoxins and spider toxins, remains to be fully characterized. Binding to these sites affects channel ion conduction or gating, and sequence differences in the residues involved contribute to subtype specificity (Catterall, 2000). Site 1 toxins such as TTX and the \( \mu \)O-conotoxins inhibit current, while most site 2–6 toxins enhance sodium current through effects on channel gating. While channel enhancers have helped to characterize gating and inactivation mechanisms of sodium channels, and the allosteric interactions between toxin binding sites, these classes of toxins invariably produce toxic effects at all doses.

The usefulness of toxins as clinically relevant drugs is limited in part by their high molecular weights and lack of subtype specificity. However, a peptide derived from tarantula venom, peptide ProTx-II is two orders of magnitude more selective for Na\(_\alpha\)1.7 compared with other heterologously expressed VGSCs and blocked action potential propagation in nociceptors (Schmalhofer et al., 2008a). Moreover, a \( \mu \)O-conotoxin selectively blocks Na\(_\alpha\)1.8 currents and chronic pain behaviour in animal models (Ekberg et al., 2006).

**Mechanisms of drug binding to voltage-gated sodium channels**

VGSCs, like other voltage-gated ion channels, can be differentially modulated by compounds that bind selectively to distinct conformational states of the channels. Upon changes in membrane potential, VGSCs undergo voltage-dependent gating that consists of a succession of conformational transitions: non-conducting closed states upon depolarization adopt an activated conducting open state followed by open-state inactivation in which the flow of ions through the channel pore is blocked by the movement of a molecular ‘ball’ into the cytoplasmic side of the newly opened pore (Armstrong and Hille, 1998) (Fig. 1). Repolarization of the membrane leads to another conformational transition, the deactivation gate (Kuo and Bean, 1994), which consists in a brief opening of the channel before reaching the closed states again. Other conformational states of VGSCs include closed-state inactivation (Armstrong, 2006), slow inactivation and for some VGSCs the ‘resurgent current’ gate. Closed-state inactivation is engaged upon small depolarizations (these allow the movement of the S4 voltage sensors in domains III and IV only, which is enough for the inactivation particle to move into the pore before the channel opens). Slow inactivation is reached during prolonged depolarizations.

Extensive mutagenesis studies of VGSCs have identified the local anaesthetic binding site as the intracellular surface of the S6 helices (Ragsdale et al., 1994, 1996), binding to which causes occlusion of the pore. The modulated receptor hypothesis (Hille, 1977) first predicted that the local anaesthetic binding site could be accessed via two distinct mechanisms: a hydrophilic pathway requiring binding of the drug from the intracellular side during channel opening and a hydrophobic pathway whereby local anaesthetics can access the water filled pore directly. Indeed, the recent crystal structure of the Arcobacter butzleri VGSC NavAb confirmed the existence of hydrophobic fenestrations within the protein lipid interface composed of fatty acyl chains (Payandeh et al., 2011, 2012). These observations suggest a molecular mechanism for closed state and use/frequency-dependent inhibition of VGSCs. Highly hydrophilic local anaesthetics have limited access to the hydrophobic pathway and instead require opening of VGSCs, allowing access of local anaesthetics to the pore and promoting binding of local anaesthetics in the inactivated state. In this case cumulative block occurs with high-frequency opening when disassociation from the local anaesthetic binding site occurs with a time constant slower than the association rate. This results in accumulation of inhibition and makes potency dependent on opening frequency. By contrast, neutral or hydrophobic local anaesthetics can access the local anaesthetic binding site through both the hydrophobic pathway when the channel is in the closed state and the hydrophilic pathway during channel opening, resulting in a combination of tonic and use-dependent blocking properties. In addition, quaternary amines such as QX-222 or QX-314 may have restricted access to the local anaesthetic binding site in accordance with the guarded receptor hypothesis (Starmer and Hollett, 1985), which may also contribute to use-dependent block. Many neurological pathological conditions result from neurons firing action potentials at higher frequencies than normal, which lead to these cells displaying a tonically depolarized membrane potential. Therefore, voltage-dependent compounds that exhibit frequency-dependent inhibition of VGSCs are desirable as they will tend to only target VGSCs in affected areas, leaving healthy tissues safe. The voltage dependence of VGSC ligands along with their pharmacokinetic properties (on and off rates) is critical in determining the mode of action of these compounds. Chemical entities with affinity for the resting state of VGSCs, like TTX, simply bind to the
extracellular regions of VGSCs, block the passage of ions and cannot be removed by either changing the membrane voltage or the gating of the channel. On the contrary, compounds with affinity for the open-inactivated state need channel opening, and therefore membrane depolarization, to bind to the inner pore of VGSCs. The pharmacokinetic properties of these ligands determine the optimal frequency at which blockade is strongest: slow dissociation rates promote use-dependent block at low frequencies, whereas fast off rates favour block at high frequencies. In other words, voltage-dependent drugs that dissociate quickly from VGSCs when the membrane potential is returned to resting values upon action potential repolarization, such as anti-epileptic VGSC blockers, are best at affecting high-frequency firing as observed in epileptic conditions. On the contrary, voltage-dependent compounds that dissociate more slowly, such as anti-arrhythmic and local anaesthetic VGSC blockers, tend to be more effective in blocking low-frequency firing.

**Sodium channel targeted drugs**

**Voltage-gated sodium channel blockers as local anaesthetics**

Cocaine was one of the first topical anaesthetics used by humans. Although cocaine is well known as a serotonin–norepinephrine–dopamine reuptake inhibitor, it also has VGSC blocking properties (Ruettsch et al., 2001). Over the years, novel VGSC blockers that can be used as local anaesthetics have been synthesized that target VGSC more specifically, have higher efficacy and have fewer side-effects. Currently, many different VGSC blockers are used as local anaesthetics such as lidocaine, bupivacaine and ropivacaine (Ruettsch et al., 2001). Local anaesthetics are weak bases that require to be injected as hydrochloride salts in acid solution to be dissolved. At the site of injection, where the pH is higher, local anaesthetics dissociate according to their pKa and release a free base. The free base is able to cross the nerve cell membrane and once inside the nerve, it becomes re-ionized due to the lower cytoplasmic pH and is unable to diffuse out of the cell (ion trapping).

The most common systemically applied local anaesthetics are lidocaine and mexiletine, which have been demonstrated to be effective drugs in treating neuropathic pain in controlled clinical studies (Challapalli et al., 2005). These anti-nociceptive effects of local anaesthetics can be observed even at plasma concentrations that would be too low to physiologically block nerve conduction. However, these low concentrations of local anaesthetics are still sufficient to block/attenuate impulse generation/ectopic discharges that cause pain while nerve conduction is unaffected (Mao and Chen, 2000). Importantly, the anti-inflammatory as well as anti-nociceptive effects of local anaesthetics cannot be explained solely by their action on VGSCs (Hollmann and Durieux, 2000; Mao and Chen, 2000). For example, systemic lidocaine enhances spinal inhibitory glycinergic neurotransmission independent of VGSC inhibition (Muth-Selbach et al., 2009).

**Subtype selective blockers to treat pain**

Naᵥ1.7 and Naᵥ1.8 have expression patterns restricted predominantly to the PNS and are both essential for normal pain transmission. Selective antagonists (Table 2) of these channels therefore make attractive targets for the treatment of pain due to the reduced chance of CNS or cardiac side-effects (although Naᵥ1.8 may play a role in cardiac conduction). A-803467 is a Naᵥ1.8 selective small molecule showing selective block of both recombinant and native Naᵥ1.8 currents (Jarvis et al., 2007). In vitro studies performed on isolated small-diameter dorsal root ganglion neurons have demonstrated that A-803467 blocks Naᵥ1.8 currents in a voltage-dependent manner and inhibits action potential firing. A-803467 shows efficacy in alleviating acute mechanical pain, inflammatory thermal hyperalgesia and neuropathic pain in rodents (Jarvis et al., 2007). These behavioural data are consistent with data showing systemic injection of A-803467 decreases both mechanically evoked and spontaneous firing of spinal neurons in nerve-injured rats (McGaraughty et al., 2008). The identification of this compound provides an important proof of concept that it is possible to develop isom-form-specific blockers of sodium channels that are analgesic. Following the development of the Naᵥ1.8 selective blocker A-830467, Abbott Labs have succeeded in developing an orally active preparations based on a modified structure of A-830467 that is effective in rodent models of neuropathic pain (Drizin et al., 2008). These compounds generally inhibited Naᵥ1.8 with IC50s in the sub-micromolar range and had some selectivity for Naᵥ1.8 over other Nav isoforms with the best compound displaying a 5-fold and 20-fold greater potency for Naᵥ1.8 over Naᵥ1.2 and Naᵥ1.3, respectively. Importantly, this class of drugs shows improved effects after oral application and better safety profiles than currently clinically used sodium channel blockers such as mexiletine and lamotrigine (Drizin et al., 2008).

Naᵥ1.7 blockers have also been developed, but the benzazepine-none structures have equipotent actions on Nav 1.2 and 1.5, suggesting that side-effects may be an issue (Williams et al., 2007). Currently, specific Naᵥ1.7 blockers are being being tested by a number of companies in human trials. For example, Convergence Pharmaceuticals are evaluating a Naᵥ1.7 inhibitor in phase II trials of trigeminal neuralgia.

A selective small molecule Naᵥ1.7 blocker (BZP) is an example of an approach to facilitate inhibition of peripherally expressed VGSCs by designing compounds that poorly penetrate the CNS (McGowan et al., 2009). BZP was demonstrated to have anti-nociceptive effects in animal models of inflammatory and neuropathic pain after oral administration, while inducing fewer CNS-related side-effects compared to mexiletine.

**State-dependent acting agents to treat pain**

Biophysical characterization of rare gain-of-function mutations affecting pain signalling has provided us with invaluable insight into the way various sodium channel blocking drugs differentially modulate the transition between the states of VGSCs. Naᵥ1.7 mutations in primary erythromelalgia and paroxysmal extreme
<table>
<thead>
<tr>
<th>Compound</th>
<th>Structure</th>
<th>IC$_{50}$</th>
<th>Mode of action</th>
<th>In vivo effects</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Imidazopyridines class</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A-803467</td>
<td><img src="image1" alt="Structure" /></td>
<td>Nav1.8: 8 nM&lt;br&gt;Nav1.2, Nav1.3, Nav1.5, and Nav1.7: $\geq 1 \mu M$</td>
<td>Voltage-dependent block; hyperpolarizing shift in steady-state inactivation; no frequency-dependent block observed</td>
<td>Attenuates neuropathic and inflammatory pain in rats</td>
<td>(Jarvis et al., 2007; McGaraughty et al., 2008)</td>
</tr>
<tr>
<td>Imidazopyridines class</td>
<td><img src="image2" alt="Structure" /></td>
<td>Compound 4:&lt;br&gt;hNav1.7: 80 nM&lt;br&gt;hNav1.8: 270 nM</td>
<td>State-dependent (inactive) channel block</td>
<td>Reversal of neuropathic pain as well as inflammatory pain in rats</td>
<td>(London et al., 2008)</td>
</tr>
<tr>
<td><strong>1-Benzazepin-2-one class</strong></td>
<td><img src="image3" alt="Structure" /></td>
<td>(Compounds 1–9): hNav1.5: 200–5000 nM&lt;br&gt;hNav1.7: 270–510 nM&lt;br&gt;hNav1.8: 130–10000 nM</td>
<td>State-dependent (inactive) channel block</td>
<td>Oral efficacy in rat model of neuropathic pain</td>
<td>(Hoyt et al., 2007; Williams et al., 2007)</td>
</tr>
<tr>
<td>Succinamide derivative BPBTS</td>
<td><img src="image4" alt="Structure" /></td>
<td>Nav1.2: 140 nM&lt;br&gt;Nav1.5: 80 nM&lt;br&gt;Nav1.7: 150 nM</td>
<td>Preferential binding to open and inactivated states; voltage- and use-dependent block; concentration-dependent hyperpolarizing shift in steady-state inactivation</td>
<td>Attenuates nociceptive behaviour in formalin test</td>
<td>(Priest et al., 2004)</td>
</tr>
<tr>
<td>Cyclopentane dicarboxamide class</td>
<td><img src="image5" alt="Structure" /></td>
<td>Compound 54 (CDA54): hNav 1.2: 430 nM&lt;br&gt;hNav 1.5: 150 nM&lt;br&gt;hNav 1.7: 250 nM&lt;br&gt;hNav 1.8: 180 nM</td>
<td>Hyperpolarizing shift of steady-state inactivation; use-dependent block</td>
<td>Inhibition of peripheral nerve injury-induced spontaneous neuronal firing. Attenuates neuropathic pain in rats</td>
<td>(Shao et al., 2005; Brochu et al., 2006)</td>
</tr>
</tbody>
</table>

(continued)
<table>
<thead>
<tr>
<th>Compound</th>
<th>Structure</th>
<th>IC₅₀</th>
<th>Mode of action</th>
<th>In vivo effects</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Furans piperazines</td>
<td>hNav1.8: 30–300 nM hNav1.2: 100–1100 nM hNav1.5: 100–4600 nM</td>
<td>Voltage-dependent block and hyperpolarizing shifts in steady-state inactivation curve; no frequency-dependent block observed</td>
<td>Analgesic effect in a rat model of neuropathic pain No adverse effects on CNS cardiovascular system</td>
<td>(Drizin et al., 2008)</td>
<td></td>
</tr>
<tr>
<td>5-Aryl-2-furfuramides</td>
<td>hNav1.8: 8 nM hNav1.3: &gt;300 nM</td>
<td>Voltage- and state-dependent (preferential affinity for the inactivated state)</td>
<td>Dose-dependent reduction of pain-related behaviour in rat models of neuropathic and inflammatory pain</td>
<td>(Kort et al., 2008)</td>
<td></td>
</tr>
<tr>
<td>TTX metabolite 4,9-anhydro-TTX</td>
<td>Nav1.2: 1.26 μmol Nav1.3: 341 nmol Nav1.4: 988 nmol Nav1.5: 78.5 μmol Nav1.6: 7.8 nmol Nav1.7: 1270 nmol Nav1.8: &gt;300 μmol</td>
<td>Hyperpolarizing shift in the voltage-dependence of steady-state inactivation</td>
<td>Not tested</td>
<td>(Rosker et al., 2007)</td>
<td></td>
</tr>
<tr>
<td>Ambroxol</td>
<td>TTXr: 35.2 μM tonic block TTXr: 22.5 μM phasic block TTXs: 111.5 μM tonic block TTXs: 57.6 μM phasic block</td>
<td>Use-dependence of block; no frequency-dependent block observed; hyperpolarizing shift in the voltage dependence of steady-state inactivation</td>
<td>Relieves pain associated with sore throat</td>
<td>(Fischer et al., 2002; Weiser and Wilson, 2002)</td>
<td></td>
</tr>
<tr>
<td>Ralfinamide</td>
<td>TTXr: 10 μM TTXs: 22 μM</td>
<td>Voltage- and state-dependent; use- and frequency-dependent block; hyperpolarizing shift in the steady-state inactivation</td>
<td>Anti-allodynic in rat models of neuropathic (chronic constriction injury) and inflammatory (complete Freund adjuvant and formalin) pain</td>
<td>(Veneroni et al., 2003; Stummann et al., 2005)</td>
<td></td>
</tr>
</tbody>
</table>

This table summarizes examples of VGSC isoform-selective compounds that have been investigated in an approach to identify potentially therapeutically useful drugs. TTXr = TTX-resistant; TTXs = TTX-sensitive.
pain disorder exhibit gain-of-function. Interestingly, patients with paroxysmal extreme pain disorder respond favourably to carbamazepine treatment, while carbamazepine is generally ineffective in patients with inherited primary erythromelalgia (Dib-Hajj et al., 2007; Fertleman et al., 2007). Paroxysmal extreme pain disorder mutations enhance recovery from inactivation and mutant channels can give rise to persistent and enhanced resurgent currents (Dib-Hajj et al., 2008; Jarecki et al., 2008; Theile et al., 2011). Carbamazepine specifically targets these deficits by shifting the voltage dependence of fast inactivation towards more hyperpolarized potentials and targets persistent currents while leaving normal currents relatively unaffected. In contrast, in most patients with inherited primary erythromelalgia, negative shifts in the voltage dependence of activation are observed. These altered properties of the channel are not affected by carbamazepine. In addition, sodium channel inhibitors such as riluzole that effectively target persistent currents and accelerate the rate of inactivation display enhanced efficacy towards inhibiting Nav\textsubscript{1.4}-peptide-mediated resurgent currents and also paroxysmal extreme pain disorder mutant currents (Theile et al., 2011). In agreement with this view, it was recently demonstrated that patients with primary erythromelalgia with a (V400M) mutation in SCN9A also display a modified VGSC fast inactivation and can be successfully treated with carbamazepine (Fischer et al., 2009).

The local anaesthetics mexiletine and lidocaine are effective in some cases of primary erythromelalgia (Iqbal et al., 2009; Kuhnert et al., 1999). Importantly, the effectiveness of these drugs can be affected by the causative mutation. For example, a specific primary erythromelalgia causing mutation (V872G) can lead to increased use-dependent block of this mutant channel, indicating some patients might have a preferable response to mexiletine (Choi et al., 2009). On the contrary, another primary erythromelalgia mutation (N395K) has been found to cause a loss in lidocaine sensitivity and this was associated with ineffectiveness of treatment with Las (Sheets et al., 2007).

Lacosamide is a novel amino acid derivative with anti-convulsant activity that is also effective as an analgesic (Stoehr et al., 2006) in several animal models of neuropathic pain (Beyreuther et al., 2006, 2007a) and as a therapy for painful diabetic neuropathy (Doty et al., 2007). Lacosamide selectively enhances sodium channel slow inactivation with no effects on fast inactivation (Errington et al., 2008) as demonstrated on recombinant Na\textsubscript{v1.3}, Na\textsubscript{v1.7} and neuronal Na\textsubscript{v1.8} currents (Sheets et al., 2008). Slow inactivation is induced under conditions of sustained depolarization and repeated firing, conditions relevant for the pathophysiology of chronic pain. The difference in affinity of lacosamide for binding inactivated channels rather than channels in the resting state was much higher than that for carbamazepine or lidocaine. Recently, it has been shown that lacosamide mediates some actions on VGSC through binding to collapsin response mediator protein 2 (now known as DPYSL2) and this interaction with collapsin response mediator protein 2 results in lacosamide-induced slowing of inactivation (Wang et al., 2010b). This novel class of VGSC blockers, which targets VGSC channels in specific conformations associated with certain pathologies, opens a new avenue of drug development that may lead to blockers of ‘pathological’ VGSCs. Recently, it has been shown that uncoupling of collapsin response mediator protein 2 from N-type voltage-gated calcium channels also suppresses inflammatory and neuropathic pain (Brittain et al., 2011). However, the relative importance of lacosamide effects on VGSC and voltage-gated calcium channels is uncertain (Wang and Khanna, 2011).

Alternative modes of action to treat pain

To limit the side-effects of VGSC blockers, one possibility is to develop compounds that target VGSCs to the desired tissue only (Clare, 2010). One example of such a drug is cyclopentane dicarbamoxide CDA54, a non-selective VGSC blocker developed by Merck (Shao et al., 2005). Oral administration of CDA54 is effective at reducing pain responses in models of inflammatory and neuropathic pain (Shao et al., 2005; Brochu et al., 2006). Importantly, after oral administration of CDA54 into rats, brain homogenate concentrations were found to be 33-fold lower than plasma concentrations, thus reducing the likelihood of side effects caused by actions within the CNS. In addition, compound 54 showed less cardiotoxicity than mexiletine (Brochu et al., 2006).

Transdermal drug application may be an advantageous way of targeting the PNS. The effectiveness of this administration route has been demonstrated by the success of lidocaine patches. Lidocaine patches are approved for the relief of pain associated with post-herpetic neuralgia and have proved efficacious in the treatment of peripheral neuropathies, lower back pain, myofascial pain, osteoarthritis, leg ulceration, erythromelalgia and carpal tunnel syndrome (Nalamachu et al., 2006).

One often undesired effect of classic VGSC blockers such as lidocaine and its derivatives is that they block action potential firing not only in nociceptive neurons after perineural injection but also in other neurons, thereby inhibiting tactile and mechanical sensation as well as motor function. Thus, targeting derivates of lidocaine specifically to nociceptive neurons, while leaving tactile and mechanical sensation unaffected, is an attractive strategy to treat pain. One strategy for selectively inhibiting nociceptors is cell-specific targeting of the quaternary lidocaine-derivative QX-314 to nociceptive neurons. QX-314 produces a long-lasting non-selective neuronal block with a slow onset (Lim et al., 2007). The slow onset of neuronal block is most probably linked to the low membrane permeability of QX-314 reducing the capacity of QX-314 to reach the intracellular blocking site of VGSCs. However, the transient receptor potential cation channel (TRPV1) agonist capsaicin facilitates the selective cellular entry of QX-314 into nociceptive sensory neurons through TRPV1, which is selectively expressed in nociceptors (Binshtok et al., 2007). By combining QX-314 with other TRPV1 agonists such as lidocaine itself or protons (lowering pH), similar effects can be achieved (Binshtok et al., 2009; Liu et al., 2011; Roberson et al., 2011). One report also showed that QX-314 itself acts as a TRPV1 agonist (Rivera-Acevedo et al., 2011). Unfortunately, intrathecal application of QX-314 causes serious irritation and death (Schwarz et al., 2010) and is twice as toxic as lidocaine when applied systemically in mice (Cheung et al., 2011). Activation of TRPV1 results in
intense pain and does therefore not appear to be the most appealing route to affect analgesia through the use of sodium channel blockers.

**Biologicals as the next generation of analgesics**

Over recent years, biological compounds such as peptides and antibodies have begun to feed into drug discovery programmes for many disease indications including pain. These include analgesic peptides based on venom toxins, which interact with VGSC. The perceived advantage of venom peptides over conventional small molecule inhibitors is that the toxins are often highly potent and efficacious (low nanomolar IC₅₀) and have a greater potential for selectivity due to their larger drug target interface. Subsequent mutagenesis of the wild-type toxin can then further improve potency and strive to improve selectivity for a given VGSC isoform. ProTx-II is a venom toxin from the tarantula *Thrixopelma pruriens* and has been reported to block Naᵥ1.7 channels (IC₅₀ = 0.3 nM) with >100-fold selectivity over other Nav isoforms (Middleton et al., 2002; Priest et al., 2007; Schmalhofer et al., 2008a). ProTx-II was effective at reducing C-fibre action potential firing frequency in an isolated skin nerve preparation in which the nerve had been de-sheathed (Schmalhofer et al., 2008b); however, no effect of ProTx-II was observed with an intact nerve sheath indicating that this peptide cannot access sodium channels in intact tissues. Intravenously applied ProTx-II was also ineffective at reducing complete Freund’s adjuvant-induced mechanical hyperalgesia. These data applied ProTx-II was also ineffective at reducing C-fibre action potential firing frequency in an isolated skin nerve preparation in which the nerve had been de-sheathed (Schmalhofer et al., 2008b); however, no effect of ProTx-II was observed with an intact nerve sheath indicating that this peptide cannot access sodium channels in intact tissues. Intravenously applied ProTx-II was also ineffective at reducing complete Freund’s adjuvant-induced mechanical hyperalgesia. These data confirm that targeting Naᵥ1.7 with a potent selective inhibitor is sufficient to dampen peripheral nociceptive drive (reduce firing of C fibres); however, due to the low permeability of ProTx-II, it is ineffective as an analgesic. Future toxin-derived analgesics targeted to peripherally expressed proteins must therefore overcome this limitation. Importantly, it is possible to use a herpes viral vector to specifically deliver biologicals to sensory neurons of the dorsal root ganglion (Fink et al., 2011).

Monoclonal antibodies targeted to essential pain pathway proteins also have the potential to revolutionize analgesic drug discovery due to their potential for high selectivity, high affinity (femtomolar range), low cardiotoxicity and long half-life (monthly subcutaneous injections are achievable). Monoclonal antibodies targeted against nerve growth factor (e.g. tanezumab, Pfizer) have successfully been used to treat chronic joint pain in osteoarthritis patients (Cattaneo, 2010). Polyclonal antibodies targeted against the second or third extracellular loop of ion channels have been successfully used as isoform selective channel blockers of TRP channels (Klionsky et al., 2006; Naylor et al., 2008), VGSCs (Chioni et al., 2005) and voltage-gated calcium channels (Liao et al., 2008). However, to date there are no published records of a therapeutically useful monoclonal antibody with ion channel blocking function, although a patent has been filed (US2011/0135662 A1) which describes a Naᵥ1.7 (E3 loop) targeted rabbit antibody which inhibits Naᵥ1.7 currents in a frequency-dependent manner, indicating that this approach may be valid.

**Voltage-gated sodium channel blockers in neurological diseases**

**Voltage-gated sodium channel blockers as anti-epileptic drugs**

Phenytoin and carbamazepine are the most widely used compounds to treat epilepsy. Both these drugs act in a state-dependent manner and slow the recovery from inactivation, thereby reducing the availability of channels for subsequent opening (Rogawski and Loscher, 2004). Phenytoin and carbamazepine are both effective in combating partial and generalized tonic-clonic seizures in humans and in animal models of these conditions (Perucca and Tomson, 2011). However, phenytoin and carbamazepine do not show efficacy against absence seizures (very brief generalized epileptic seizures of sudden onset and termination) both in humans and in the animal models of this condition (Dreifuss, 1983; Mantegazza et al., 2010). Phenytoin is most effective at depolarized membrane potentials and high-frequency action potential firing. The state dependence of phenytoin causes minimal effects on cognitive functions (low-frequency firing). Carbamazepine displays the same pharmacological properties as phenytoin (VGSC specificity, voltage and state dependence). However, carbamazepine binds VGSCs less effectively, but with a much faster rate than phenytoin, rendering carbamazepine more effective in blocking high-frequency firing (Mantegazza et al., 2010). These differences in properties might explain why some epileptic patients respond better to one or the other drug if they carry different VGSC mutations.

Lamotrigine, like phenytoin and carbamazepine, is effective against partial and generalized tonic–clonic seizures and also shows efficacy for the treatment of absence seizures and Lennox–Gastaut syndrome, a rare and intractable form of childhood epilepsy associated with learning difficulties. The mode of action of lamotrigine on VGSCs is similar to that of phenytoin and carbamazepine (voltage and use dependence). However, lamotrigine also acts on other molecular targets, such as the hyperpolarization-gated cationic current Ih in dendrites of pyramidal neurons (Poulos et al., 2002), N- and P-type voltage-gated Ca²⁺ channels in cortical neurons (Stefani et al., 1996) and neocortical potassium currents (Zona et al., 2002). Therefore, the anti-epileptic action of lamotrigine may have a different biophysical basis to carbamazepine and phenytoin.

Topiramate, a sulphamate derivative of the naturally occurring sugar D-fructose, is another broad-spectrum anti-epileptic drug prescribed in cases of partial and generalized tonic–clonic seizures. It blocks both VGSCs and voltage-gated Ca²⁺ channels and enhances potassium channel activity (Shank and Maryanoff, 2008). Interestingly, the action of topiramate on VGSCs consists of slowing down the opening of the channels and protein kinase C activation limits the effect of topiramate of blocking persistent sodium currents (Curia et al., 2004).
Introduced as an anti-epileptic drug in 1962, valproate has an even more extensive range of pharmacological actions, being effective against partial and generalized tonic-clonic seizures, absence seizures, and myoclonic seizures. Valproate is a widely prescribed anti-epileptic drug, in both adults and children, and its success is likely to be due to modes of actions different from blocking VGSCs. However, valproate selectively inhibits persistent sodium currents over transient ones in neocortical and sympathetic neurons (Tavera et al., 1998; Lamas et al., 2009), although the exact mechanism remains unknown. In part, its therapeutic effects are caused by increases in the turnover of GABA, inhibition of NMDA (N-methyl-D-aspartic acid) receptors and reduction in gamma-hydroxybutyrate release (Maitre, 1997).

Riluzole was first developed as an anti-epileptic drug but is now used as the first-in-line drug for treatment of amyotrophic lateral sclerosis. It has neuroprotective effects due to blockade of VGSCs on presynaptic terminals and enhancing glutamate uptake by astrocytes thereby inhibiting glutamatergic transmission. Additionally, riluzole has been demonstrated recently to protect against cardiac ischaemia and reperfusion injury by inhibiting persistent sodium currents and is now being tested as a possible treatment for psychiatric disorders (Pittenger et al., 2008; Weiss et al., 2010).

**Voltage-gated sodium channel blockers for the treatment of migraine**

Migraine is thought to originate from the activation of meningeal and blood vessel nociceptive fibres, in conjunction with neurogenic inflammation and a change in central pain modulation (Kalra and Elliott, 2007). In common with epilepsy, migraine is characterized by recurrent episodes of nervous system dysfunction with a return to baseline between attacks. Rare forms of familial migraine are caused by mutation of SCN1A (Dichgans et al., 2005; Vahedi et al., 2009). Migraine is treated with a wide range of drugs, including triptans that, through their agonist effects on serotonin receptors, block the release of vasoactive neuropeptides such as CGRP. Other treatments include the use of non-steroidal anti-inflammatory drugs, anti-depressants and neuropeptides such as CGRP. Other treatments include the use of non-steroidal anti-inflammatory drugs, anti-depressants and calcium channel blockers (Bolcskei et al., 2009). Epilepsy is a co-morbid condition of migraine. Several anti-epileptic drugs targeting VGSCs have been tested for efficacy in migraine conditions. Anti-epileptic compounds, such as valproate, topiramate and lamotrigine, which act through VGSC, have been shown to be effective at reducing the frequency of migraine attacks. However, these drugs all act on other targets as well and therefore their therapeutic effect may be unrelated to their effect on VGSCs (Calabresi et al., 2007). It is important to note that use-dependent selective VGSC blockers, such as phenytoin and carbamazepine, have not been documented to be efficacious against migraine attacks (Rogawski and Loscher, 2004). Finally, intranasal application of the local anaesthetic and anti-arrhythmic compound lidocaine was reported to be an effective treatment for some refractory migraines (Kudrow et al., 1995; Bolcskei et al., 2009).

**Voltage-gated sodium channel blockers in neurodegenerative disorders and neuroinflammation**

Multiple sclerosis is a condition that may be linked to an autoimmune reaction. However, drug treatment to suppress immune responses is of limited effectiveness. Neurodegeneration as a consequence of progression of multiple sclerosis also involves the activation of VGSCs (Smith, 2007). In particular, demyelination of axons that occurs in patients with multiple sclerosis leads to ectopic action potential firing that is caused by slow sodium-dependent membrane potential oscillations (Kapoor et al., 1997).

VGSCs have also been implicated in anoxia/injury-induced neurodegeneration. Energy loss leads in part to persistent sodium currents that cause an increase in axonal intracellular sodium leading to membrane depolarization and further activation of VGSCs. These events promote the reversal of Na⁺/Ca²⁺ exchanger and overload of axonal calcium (Stys, 2004).

VGSC blockers such as TTX, lidocaine, procaine, mexiletine, phenytoin and carbamazepine protect against white matter axonal damage in multiple sclerosis models (Waxman et al., 1994a; Carter, 1998; Hewitt et al., 2001; Kapoor et al., 2003; Black and Waxman, 2008). These protective effects can be observed at concentrations that do not compromise the conduction of action potentials. Lidocaine and flecainide can also protect axons from nitric oxide-triggered degeneration (Kapoor et al., 2003). However, withdrawal of phenytoin or carbamazepine in experimental autoimmune encephalomyelitis, a mouse model for multiple sclerosis, resulted in increased inflammatory infiltrate, worsening of symptoms and high incidence of mortality, leading to the suspension of clinical trials (Black and Waxman, 2008). In other trials, lamotrigine did not positively affect clinical outcome measures of patients with secondary progressive multiple sclerosis (Kapoor et al., 2010).

Other clinical trials involving a combined therapy with interferon β1a and topiramate, riluzole and lamotrigine, respectively, are still ongoing (Conway and Cohen, 2010). Thus, whether VGSC blockers will ultimately provide an effective new strategy for the treatment of multiple sclerosis is unclear.

Effects of VGSC blockers might also occur through inhibition of phagocytic functions of microglia. Expression of Na₉/1.6 is upregulated in activated microglia and inhibition of VGSC reduces their phagocytic capacity and reduces inflammatory cells infiltration in brain tissue of mice with experimental autoimmune encephalomyelitis (Craner et al., 2005).

Na₉/1.5 is present in late endosomes of human macrophages, which play an important role in phagocytosis. Na₉/1.6 is also expressed in macrophages where it associates with the cytoskeleton, possibly aiding macrophage motility (Carrithers et al., 2007). VGSCs were also shown to have a role in T-lymphocyte motility (Fraser et al., 2004). However, given the possible side-effects, the value of VGSC blockers to modulate immune responses is unclear (Rosell et al., 2006).
<table>
<thead>
<tr>
<th>Compound</th>
<th>Structure</th>
<th>Clinical indications</th>
<th>Mode of action</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lidocaine</td>
<td><img src="image1" alt="Structure" /></td>
<td>Widely used local anaesthetic; Class 1b anti-arrhythmic drug; status epilepticus; neuropathic pain</td>
<td>Frequency-dependent, state-dependent and voltage-dependent block; hyperpolarizing shift of half-maximal inactivation</td>
<td>(Durham, 1999; Mao and Chen, 2000; Sheets et al., 2008)</td>
</tr>
<tr>
<td>Phenytoin</td>
<td><img src="image2" alt="Structure" /></td>
<td>Second/third line therapy of generalized tonic-clonic seizures; Class 1b anti-arrhythmic drug</td>
<td>Slowing of recovery from inactivation; voltage-dependent and frequency-dependent block</td>
<td>(Schwarz and Grigat, 1989)</td>
</tr>
<tr>
<td>Carbamazepine</td>
<td><img src="image3" alt="Structure" /></td>
<td>Epilepsy (tonic-clonic and partial seizures); trigeminal neuralgia; neuropathic pain in general and SCN9A-related painful channelopathies in particular</td>
<td>Frequency-dependent and voltage-dependent block; slowing of recovery from inactivation; partial block of persistent sodium currents in a concentration-dependent manner</td>
<td>(Mattson et al., 1985; Smith et al., 1987; Schwarz and Grigat, 1989; Fertleman et al., 2007; Sun et al., 2007; Sheets et al., 2008; Fischer et al., 2009; Wiffen et al., 2011)</td>
</tr>
<tr>
<td>Lacosamide</td>
<td><img src="image4" alt="Structure" /></td>
<td>Diabetic painful neuropathy; adjunct anti-epileptic therapy</td>
<td>Enhances slow inactivation; no effect on fast inactivation</td>
<td>(Ben-Menachem et al., 2007; Rauck et al., 2007; Sheets et al., 2008)</td>
</tr>
<tr>
<td>Lamotrigine</td>
<td><img src="image5" alt="Structure" /></td>
<td>First-line therapy of generalized tonic-clonic, absence, tonic and atonic seizures</td>
<td>Hyperpolarizing shift in voltage-dependency of steady-state inactivation</td>
<td>(Zona et al., 2002; French et al., 2004)</td>
</tr>
<tr>
<td>Topiramate</td>
<td><img src="image6" alt="Structure" /></td>
<td>Generalized tonic-clonic, myoclonic, focal with/without secondary generalization seizures; neuropathic pain</td>
<td>Partial block of persistent sodium currents</td>
<td>(Zona et al., 2002; Chong and Libretto, 2003; Khoromi et al., 2005)</td>
</tr>
</tbody>
</table>

(continued)
<table>
<thead>
<tr>
<th>Compound</th>
<th>Structure</th>
<th>Clinical indications</th>
<th>Mode of action</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zonisamide</td>
<td><img src="image1" alt="Zonisamide Structure" /></td>
<td>Adjunctive treatment of partial seizures in adults; promising, but not licensed in treatment of refractory neuropathic pain in adults</td>
<td>Hyperpolarizing shift in voltage-dependence of fast inactivation; reduces sustained high-frequency repetitive firing of action potentials</td>
<td>(Hasegawa, 2004; Leppik, 2004; Biton, 2007)</td>
</tr>
<tr>
<td>Amitriptyline</td>
<td><img src="image2" alt="Amitriptyline Structure" /></td>
<td>First-line treatment for neuropathic pain in the UK</td>
<td>Hyperpolarizing shift in voltage-dependence of fast inactivation</td>
<td>(Graff-Radford et al., 2000; Song et al., 2000; Cardenas et al., 2002; Robinson et al., 2004)</td>
</tr>
<tr>
<td>Procainamide</td>
<td><img src="image3" alt="Procainamide Structure" /></td>
<td>Class 1a anti-arrhythmic drug.</td>
<td>Use-dependent block</td>
<td>(Giardina, 1984; Harmer et al., 2011)</td>
</tr>
<tr>
<td>Mexiletine</td>
<td><img src="image4" alt="Mexiletine Structure" /></td>
<td>Class 1b anti-arrhythmic drug; neuropathic pain in general and SCN9A-related painful channelopathies in particular</td>
<td>Hyperpolarizing shift in voltage-dependent channel inactivation state-dependent and use-dependent block</td>
<td>(Campbell, 1987; Jang et al., 2004; Ebell, 2006; Choi et al., 2009)</td>
</tr>
<tr>
<td>Flecaïnide</td>
<td><img src="image5" alt="Flecainide Structure" /></td>
<td>Class 1c anti-arrhythmic agent; Phase II trial data for chronic neuropathic pain</td>
<td>Use-dependent block</td>
<td>(Wang et al., 1993; von Gunten et al., 2007; Harmer et al., 2011)</td>
</tr>
</tbody>
</table>

Although many of these blockers also act through mechanisms other than blocking VGSCs, only VGSC-related indications and mechanisms are reported.
Voltage-gated sodium channel blockers in neuromuscular disorders

Currently, 12 channelopathies affecting skeletal muscle have been described. All five VGSC channelopathies affecting skeletal muscle are found in SCN4A/NaV1.4 (Jurkat-Rott et al., 2010). These channelopathies, as described earlier, are classified as potassium-aggravated myotonia, paramyotonia congenita, hyperkalaemic periodic paralysis, hypokalaemic periodic paralysis and a form of congenital myasthenic syndrome. Depending on the functional consequence of the mutation (gain- or loss-of-function), treatment options are to either use VSGC blockers to directly block the channel or to reduce the fraction of inactivated channels by restoring the skeletal muscle membrane potential (Jurkat-Rott et al., 2010). Pharmacological treatment in myotonia is aimed at decreasing muscle stiffness by mitigating the involuntary action potential bursts without blocking voluntary high-frequency muscle stimulation (Jurkat-Rott et al., 2010). VGSC blockers reduce muscle stiffness in potassium-aggravated myotonia and paramyotonia congenita by promoting the inactivated state of NaV1.4 by inducing a hyperpolarized shift in steady-state inactivation and by prolonging recovery time from inactivation. VSGC blockers such as mexiletine, flecainide and other lidocaine analogues can reduce repetitive firing of action potential because of their use-depended properties, a mechanism that leads to a preferential action on channels with pathogenic gain-of-function mutations (Mohammadi et al., 2005). Symptoms of muscle weakness are often caused by other pathogenic factors and cannot be treated sufficiently with VGSC blockers. However, influencing potassium concentration or blocking potassium channels have been proven to be beneficial (Jurkat-Rott et al., 2010). Burge and Hanna (2012) performed a more detailed analysis of mechanisms and therapeutic options in neuromuscular disorders.

Voltage-gated sodium channel blockers in non-neurological diseases

Voltage-gated sodium channel blockers as anti-arrhythmic drugs

VGSCs are important therapeutic targets in the management of cardiac arrhythmias. According to the Singh Vaughan Williams classification (Walker, 2006), the group of anti-arrhythmic drugs is subdivided into four categories depending on whether they block VGSCs, β-adrenergic receptors, potassium channels or Ca²⁺ channels. Class I anti-arrhythmics are primarily VGSC blockers that are further subdivided into three subclasses (Nattel, 1993), based upon their effect on the length of the action potential. VGSCs blockers as anti-arrhythmic drugs have been discussed extensively previously (Ganjehei et al., 2011)

Potential dangers of voltage-gated sodium channel blockers on human development

A missense mutation in the SCN9A gene encoding NaV1.7 has been linked to abnormal limb development (Hoeijmakers et al., 2012). Some VGSC blockers may have teratogenic effects. Anti-epileptic medication during pregnancy might elevate the risk for congenital malformations, particularly when the treatment involves multiple compounds and/or valproate (Morrow et al., 2006). Anti-epileptic treatment with valproate during pregnancy was also linked to significantly lower intelligence in children (Bromley et al., 2009). Lacosamide is not used in young children because it was demonstrated to interact with the collapsin response mediator protein 2, which is involved in neuronal differentiation and control of axonal growth (Beyreuther et al., 2007b; Wang et al., 2010b).

Conclusions and future directions

Sodium channel blockers originally derived from cocaine, such as lidocaine, have been in clinical use for more than a century. Progress in understanding the molecular basis of channel activity and the mechanisms of action of some analgesic drugs that have been found to act on sodium channels have provided a clear framework on which to pursue medicinal chemistry approaches. Toxins also provide important models for the development of novel analgesic families, based on natural peptides or on organic peptidomimetics. Recent advances in the development of orally active small molecule-specific NaV1.8 blockers will eventually be followed by antagonists of NaV1.7 and NaV1.9. In the meantime the state-dependent blocker lacosamide looks set to join the broad-spectrum sodium channel blockers already in clinical use in Europe. While pain control and epilepsy are still the major focus of interest in terms of sodium channel drug development, it remains possible that indications ranging from autism to immune disorders may be modulated by compounds targeted at sodium channel activity. Manipulation of VGSCs in particular cell types is desirable for many of these indications, as global channel blocking is likely to have deleterious consequences. Topical application, targeted delivery or drugs that lower functional channel expression are all potential future approaches to these problems.

Acknowledgements

We thank members of the Molecular Nociception Group and London Pain Consortium for helpful comments.

Funding

J.N.W. thanks the Medical Research Council, The Wellcome Trust and the Biochemistry and Biotechnology Research Council for generous financial support. N.E. is supported by a Rubicon fellowship of The Netherlands Organisation for Scientific Research (NWO).
R.W. is supported by a research fellowship (We 4860/1-1) from Deutsche Forschungsgemeinschaft, Bonn, Germany.

References


Grieco TM, Malhotra JD, Chen C, Isom LL, Raman IM. Open-channel block by the cytoplasmic tail of sodium channel beta4 as a mechanism for resurgent sodium current. Neuron 2005; 45: 233–44.

Grieco TM, Raman IM. Production of resurgent current in Nav1.6-null Purkinje neurons by slowing sodium channel inactivation with beta-pomplidotoxin. J Neurosci 2004; 24: 35–42.


Herfst LJ, Potet F, Bezzina CR, Groenewegen WA, Le MH, Hoornije TM, et al. Na+ channel mutation leading to loss of function and non-


Isom LL. The role of sodium channels in cell adhesion. Front Biosci 2002; 7: 12–23.


Leo S, D’Hoore R, Meert T. Exploring the role of nociceptor-specific sodium channels in pain transmission using Nav1.8 and Nav1.9 knockout mice. Behav Brain Res 2010; 208: 149–57.


Roberson DP, Binshtok AM, Blasf F, Bean BP, Woolf CJ. Targeting of sodium channel blockers into nociceptors to produce long-duration


sodium currents studied in HEK293 cells expressing the Na(v)1.3 alpha-subunit. Epilepsia 2007; 48: 774–82.
Waxman SG, Kocsis JD, Black JA. Type III sodium channel mRNA is expressed in embryonic but not adult spinal sensory neurons, and is reexpressed following axotomy. J Neurophysiol 1994b; 72: 466–70.
Wong HK, Sakurai T, Oyama F, Kaneko K, Wada K, Miyazaki H, et al. beta Subunits of voltage-gated sodium channels are novel substrates...
Zhao J, O’Leary ME, Chahine M. Regulation of Na(v)1.6 and Na(v)1.8 peripheral nerve Na(+) channels by auxiliary beta-subunits. J Neurophysiol 2011; 106: 608–19.